Supplements
How Often Should IGF-1 Be Tested?
IGF-1 is one of the most stable and informative longevity biomarkers available, yet most people either never test it or test it far too frequently. Getting the cadence right — matched to your clinical context — is what separates useful data from expensive noise.

How Often Should IGF-1 Be Tested?
For most healthy adults, once per year is a reasonable testing frequency — but the right answer depends heavily on context. If you have symptoms of growth hormone dysregulation, are managing a chronic condition, or have recently changed a diet or supplement protocol that influences IGF-1, retesting every three to six months gives more actionable data. People with known pituitary disorders or active cancer surveillance follow stricter schedules set by their physician.
What Is IGF-1 and Why Does It Matter?
Insulin-like Growth Factor 1 (IGF-1) is a peptide hormone produced primarily in the liver in response to growth hormone (GH) signaling. Unlike GH itself, which pulses throughout the day in 4–8 discrete secretory bursts, IGF-1 circulates at relatively stable concentrations — which is exactly what makes it a superior biomarker. A single blood draw accurately reflects integrated GH secretion over days rather than capturing a single pulse.
IGF-1 mediates most of the anabolic effects traditionally attributed to GH: muscle protein synthesis, bone mineralization, cellular proliferation, and metabolic regulation. It binds to IGF-1 receptors on nearly every tissue type, making it relevant to contexts far beyond pediatric growth medicine — including metabolic health, cardiovascular risk stratification, cognitive aging, and longevity research. The IGF-1 receptor shares significant structural homology with the insulin receptor, which partly explains why states of chronic hyperinsulinemia tend to co-elevate IGF-1, and why fasting and caloric restriction reliably suppress it even when GH secretion remains intact.
Reference ranges are age- and sex-adjusted because IGF-1 peaks during puberty (roughly ages 14–17) and declines progressively through adulthood — at approximately 1–2% per year after age 30, mirroring the decline in GH pulse amplitude. A 55-year-old with an IGF-1 of 120 ng/mL sits squarely in a normal range; that same number would signal a problem in a 17-year-old.
IGF-1 Blood Test: What the Draw Actually Measures
The IGF-1 blood test is a serum assay, typically drawn fasting or under standardized conditions because recent high-carbohydrate or high-protein meals can transiently shift IGF-1. Most commercial labs (Quest Diagnostics, LabCorp) report results alongside age- and sex-matched reference intervals.
Key pre-test considerations:
- Fasting for at least 8 hours is recommended at many labs, though some studies suggest the effect of a single meal is modest (less than 10% variation).
- Acute illness, prolonged fasting (>24 hours), or severe caloric restriction suppresses IGF-1 independently of GH status.
- Extreme exercise in the 24 hours prior can transiently elevate results.
- Some medications — insulin, estrogen, corticosteroids — alter IGF-1 independent of pituitary function.
When tracking IGF-1 serially, drawing under consistent conditions (same lab, same fasting duration, same time of day) reduces noise and makes trend interpretation more reliable. The intra-individual coefficient of variation for IGF-1 on a single immunoassay platform is typically 5–8%, meaning changes smaller than that threshold may reflect assay noise rather than a genuine physiological shift — a practical argument against testing more than once every 8–12 weeks except in acute clinical scenarios.
Typical adult reference ranges by decade (approximate):
| Age Range | Low (ng/mL) | Normal (ng/mL) | High (ng/mL) |
|---|---|---|---|
| 20–29 | <115 | 115–307 | >307 |
| 30–39 | <100 | 100–267 | >267 |
| 40–49 | <88 | 88–233 | >233 |
| 50–59 | <71 | 71–200 | >200 |
| 60–69 | <58 | 58–172 | >172 |
| 70+ | <46 | 46–150 | >150 |
Ranges vary by laboratory and assay method. Always interpret against the reference interval provided by your specific lab.
How Often Should IGF-1 Be Tested? A Decision Framework
There is no universal guideline equivalent to the American Diabetes Association's annual HbA1c recommendation — IGF-1 testing frequency is individualized. The following framework synthesizes clinical endocrinology practice and preventive-medicine principles:
Scenario 1 — Healthy adult, no symptoms, general longevity monitoring
Once per year as part of a comprehensive metabolic panel is sufficient. IGF-1 declines gradually (roughly 1–2% per year after age 30), so quarterly testing in asymptomatic individuals generates noise without actionable signal.
Scenario 2 — Investigating symptoms of growth hormone deficiency or excess
Baseline plus a follow-up at 3 months after any intervention (dietary change, medication, peptide protocol). If the follow-up confirms the trajectory, annual monitoring resumes.
Scenario 3 — Managing diagnosed GH deficiency on GH replacement therapy
Every 3–6 months per Endocrine Society guidelines (Molitch et al., Journal of Clinical Endocrinology & Metabolism 2011; PMID: 21602453). The goal is to titrate GH dose to maintain IGF-1 within the age-adjusted normal range without overshoot. In the KIMS pharmacoepidemiological study — the largest real-world GH replacement registry — mean IGF-1 SDS was used as the primary dosing endpoint in over 13,000 patients, reinforcing the biomarker's clinical utility for treatment monitoring (Abs et al., Journal of Clinical Endocrinology & Metabolism 2006; PMID: 16608896).
Scenario 4 — Cancer surveillance or history of acromegaly
Frequency is set by the treating oncologist or endocrinologist. High IGF-1 is associated with colorectal, breast, and prostate cancer risk in epidemiological data (Renehan et al., Lancet 2004; PMID: 15016485), though IGF-1 alone is not a cancer screening tool.
Scenario 5 — Tracking a lifestyle, dietary, or supplement intervention
Baseline → 8–12 weeks post-intervention → assess. This interval aligns with hepatic IGF-1 synthesis kinetics and is long enough for most nutritional interventions to show a measurable effect. For example, controlled trials examining the effect of protein supplementation on IGF-1 have used 8–12 week windows as the minimum duration to detect statistically significant changes in serum IGF-1 (Holt et al., European Journal of Clinical Nutrition 2003; PMID: 12947434).
If you're also monitoring cardiovascular risk markers, pairing your IGF-1 panel with lipid biomarkers makes sense — see the guide on how often LDL should be tested for context on building an integrated testing schedule. Similarly, elevated fasting glucose often co-occurs with high-normal IGF-1 through shared insulin-resistance pathways; the article on how often fasting glucose should be tested covers the complementary retesting logic.
Symptoms of Low IGF-1
Below-range IGF-1 — sometimes called somatotropin deficiency when GH is involved — produces a recognizable clinical picture, though the symptoms overlap with hypothyroidism, low testosterone, and other deficiency states, which is why a blood test is essential for differentiation.
Common symptoms of low IGF-1 in adults include:
- Persistent fatigue and reduced stamina disproportionate to activity level
- Loss of lean muscle mass and increased central adiposity despite unchanged diet
- Reduced bone mineral density and increased fracture risk
- Impaired recovery from exercise or injury
- Cognitive fog, reduced working memory, and low mood
- Decreased libido
- Thin, dry skin and reduced collagen density
A landmark study by Johannsson and colleagues demonstrated that GH-deficient adults had significantly impaired quality of life across all these domains, and that GH replacement normalizing IGF-1 improved body composition, bone density, and self-reported well-being (Johannsson et al., Journal of Clinical Endocrinology & Metabolism 1996; PMID: 8855804). Specifically, after 12 months of GH replacement targeting age-adjusted IGF-1, lean body mass increased by approximately 3–4 kg while fat mass decreased by a comparable amount, and bone turnover markers improved significantly.
Nutritional causes of low IGF-1 are common and underappreciated. Protein restriction, prolonged caloric deficit, and zinc deficiency all suppress hepatic IGF-1 production independent of GH status. A foundational review by Thissen et al. documented that dietary protein is the primary nutritional modulator of IGF-1, with low-protein diets reducing IGF-1 by 30–40% even when caloric intake is adequate (Thissen et al., Endocrine Reviews 1994; PMID: 8156941). The mechanism involves downregulation of GH receptor expression in the liver and reduced JAK2-STAT5 signaling — the intracellular cascade that drives IGF-1 transcription — when amino acid availability is insufficient. This matters because correcting a nutritional cause costs nothing and requires no prescription. Understanding related micronutrient shortfalls is worth reviewing — zinc deficiency symptoms and immune function covers how zinc interacts with growth hormone signaling in useful detail.
CRP elevation often accompanies states of low IGF-1, since chronic inflammation suppresses the GH–IGF-1 axis at the hepatic level through interleukin-1β and TNF-α signaling, which directly inhibit GH receptor expression. If you're investigating low IGF-1, checking your inflammatory markers in parallel adds important context — the guide on how often CRP should be tested explains the optimal retesting cadence.
Symptoms of High IGF-1
Below-range IGF-1 gets more clinical attention, but symptoms of high IGF-1 — particularly chronically elevated levels — carry their own risks that often go underrecognized in the functional medicine space.
Pathologically elevated IGF-1 is the hallmark of acromegaly (excess GH from a pituitary adenoma), but milder functional elevations occur with high dairy intake, elevated insulin states, obesity-associated insulin resistance, and exogenous GH or IGF-1 peptide use.
Symptoms and signs associated with elevated IGF-1:
- Coarsening of facial features, enlarged hands and feet (in frank acromegaly)
- Excessive sweating and oily skin
- Joint pain and carpal tunnel syndrome
- Fatigue paradoxically coexisting with elevated anabolic hormone levels
- Headaches (pituitary pressure in acromegaly)
- Increased soft tissue and organ growth
- Elevated fasting glucose and insulin resistance
At the epidemiological level, men in the top quartile of IGF-1 had a relative risk of prostate cancer 2.4 times higher than those in the bottom quartile in the landmark Renehan et al. meta-analysis cited earlier. Similar associations were found for colorectal cancer in both sexes across 21 prospective studies. This does not make IGF-1 a clinical cancer test, but it does underscore why indefinitely high IGF-1 — sometimes promoted in performance circles as categorically desirable — requires a more nuanced interpretation.
Functionally elevated IGF-1 without clear pituitary pathology is increasingly observed in people following very high-protein diets (>2.5 g/kg body weight), particularly from animal sources, alongside high insulin load. A 2017 epidemiological analysis found that plant-based protein sources raised IGF-1 significantly less than equivalent quantities of animal protein, with dairy protein appearing to be the strongest dietary driver of circulating IGF-1 in adults (Levine et al., Cell Metabolism 2014; PMID: 24606898). This has practical implications: if your IGF-1 is persistently high-normal without a prescription drug or peptide explanation, a dietary audit before retesting in 8–12 weeks is warranted before escalating to endocrinology referral.
In people with insulin resistance, the relationship between IGF-1 and blood glucose regulation is bidirectional. Because IGF-1 has insulin-mimetic effects through shared receptor signaling, chronically supraphysiologic IGF-1 can paradoxically worsen fasting glucose by down-regulating pancreatic beta-cell insulin secretion through negative feedback. Pairing an IGF-1 retest with a fasting glucose and fasting insulin panel captures this interaction cleanly.
What This Means for Your Formula
IGF-1 is not a direct supplement target in the way that, say, thyroid hormones respond to selenium. However, several modifiable inputs that influence IGF-1 do fall within the scope of a personalized supplement protocol.
Zinc is perhaps the most direct micronutrient modulator of IGF-1. Zinc is required for GH receptor dimerization and downstream JAK2 kinase activation — the same pathway that drives hepatic IGF-1 synthesis. Studies in zinc-deficient adolescents and young adults show that repletion raises IGF-1 meaningfully even without changes in GH secretion itself. Ones includes zinc as a standalone ingredient dosed to clinical ranges, with amounts calibrated to the individual's serum zinc level and dietary intake pattern rather than applied as a blanket dose.
Vitamin D3 + K2 (MK-7) supports IGF-1 biology through a separate mechanism: vitamin D receptor signaling in the pituitary modulates GH pulse amplitude, and observational data consistently show positive correlations between 25-OH-D status and serum IGF-1 in adults over 50. Ones pairs D3 with MK-7 to support the vascular and bone co-factors that IGF-1 targets — particularly relevant for the low-IGF-1 phenotype where bone turnover and arterial calcification risk both shift unfavorably.
Omega-3 fatty acids (EPA/DHA) do not directly raise or lower IGF-1, but they modulate the inflammatory cytokines — particularly IL-6 and TNF-α — that suppress hepatic GH receptor expression and therefore limit IGF-1 output in chronically inflamed individuals. Reducing that inflammatory suppression is one plausible mechanism by which Omega-3 supplementation indirectly supports healthier IGF-1 expression in people with elevated CRP. Ones includes pharmaceutical-grade EPA/DHA dosed based on the individual's omega-3 index from wearable and lab data where available.
When an AI health platform like Ones analyzes your blood work alongside wearable trends, it can flag the pattern — low IGF-1 combined with low zinc, low vitamin D, and elevated CRP — and address all three inputs simultaneously rather than treating each in isolation.
Key Takeaways
- For healthy adults, annual IGF-1 testing is sufficient; quarterly testing without clinical indication produces noise, not insight.
- For people on GH replacement therapy or managing acromegaly, every 3–6 months per Endocrine Society guidelines is the evidence-based cadence.
- Symptoms of low IGF-1 — muscle loss, fatigue, poor recovery, cognitive fog — frequently have nutritional causes (low protein, zinc deficiency) that are worth ruling out before assuming pituitary pathology.
- Symptoms of high IGF-1 — joint pain, glucose dysregulation, excessive sweating — can appear even without frank acromegaly, and persistent high-normal levels warrant a dietary audit and physician review.
- The 8–12 week retest window after any lifestyle or supplement intervention is the minimum needed to see meaningful, signal-to-noise-clear changes in serum IGF-1.
- Testing IGF-1 alongside CRP, fasting glucose, and zinc gives a far more complete mechanistic picture than IGF-1 in isolation — these biomarkers sit on intersecting pathways and should ideally be reviewed together.